Use of RWD and RWE to Support Drug Reimbursement Decision-Making in Asia

The REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group is drafting a new report entitled ‘Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia’. The report is focused on drug assessments and the use of RWD/RWE as complementary evidence to randomized controlled trials (RCTs), the current gold standard for generating evidence on treatment efficacy.

A collaboration between global experts and 11 Asian health systems, the REALISE group has developed non-binding guidance to provide a framework to generate and use real-world data (RWD) / real-world evidence (RWE) in a consistent and efficient manner for drug reimbursement decision-making in Asia. Find out more here.